Zymeworks BC Inc [ZYME] stock is trading at $12.43, up 5.16%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZYME shares have gain 7.06% over the last week, with a monthly amount glided 5.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, JP Morgan upgraded its rating to Overweight on December 16, 2024, and kept the price target unchanged to $18. On November 07, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $25 on the stock. Wells Fargo downgraded its rating to a Equal Weight but stick to its price target of $12 on November 01, 2024. H.C. Wainwright reiterated a Neutral rating for this stock on January 04, 2023, and downed its price target to $8. In a note dated December 20, 2022, Jefferies upgraded an Buy rating on this stock and boosted its target price from $7.70 to $11.
Zymeworks BC Inc [ZYME] stock has fluctuated between $8.21 and $17.70 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $12.43 at the most recent close of the market. An investor can expect a potential return of 109.17% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 93.38M for the trailing twelve months, which represents a growth of 170.29%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.15%, Pretax Profit Margin comes in at -1.15%, and Net Profit Margin reading is -1.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.32 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Zymeworks BC Inc’s Current Ratio is 4.71. In addition, the Quick Ratio stands at 4.71 and the Cash Ratio stands at 1.17. Considering the valuation of this stock, the price to sales ratio is 9.35, the price to book ratio is 2.68.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on May 15 ’25 when 49502.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on May 19 ’25 to buy 5919.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 73953.0 shares on Apr 16 ’25.
